We recently published 10 Stocks With Massive Gains; 5 at record levels. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one of the top performers on Wednesday.
Recursion extended its winning streak to a fourth day on Wednesday, jumping 6.81 percent to close at $4.86 apiece, as investors gobbled up more shares ahead of expected trading updates from its participation in two conferences next week.
In a statement on Tuesday, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) said its president and CEO, Najat Khan, would present at the 44th Annual JP Morgan Healthcare Conference in San Francisco on Tuesday, January 13, as well as the 28th Annual Needham Growth Conference on Friday, January 16.
Employees working at the Recursion Pharmaceuticals headquarters. Photo by Recursion Pharmaceuticals
Investors will be watching for updated guidance on its earnings performance in 2025, updates on its pipeline, and its outlook for 2026.
Last month, investment firm JPMorgan turned bullish on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) after previously upgrading the stock from “neutral” to “overweight,” while also raising its price target to $11 from $10.
The change came following strong results from the latest clinical trial of the therapy candidate, REC-4881, which aims to treat familial adenomatous polyposis.
According to JPMorgan, REC-4881 has the potential to generate $1 billion in sales in the United States.
While we recognize the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks have more promise to generate higher returns and have limited downside risk. If you’re looking for an extremely cheap AI stock that’s also one of the biggest beneficiaries of Trump’s tariffs and offshoring, check out our free report on the best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.